IPCA Unveils New Product for Diabetic Foot Ulcers

IPCA Laboratories Ltd launched Diulcus, a new product for the treatment of Diabetic Foot Ulcer in the Indian market. The drug developed by NovaLeadPharmaPvt Ltd—recognized globally for repurposing drugs—received approval from the Central Drugs Standard Control Organization (CDSCO) and partial funding from Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

This comes at a time when India is challenged by the current health condition; more than 236 million people are suffering from diabetes and pre-diabetes. The launch of Diulcus is expected to make a huge difference in DFU management. In phase 3 trials conducted in India, Diulcus managed to attain a 60.3 percent ulcer closure rate within three months. That is quite a landmark. Astoundingly, this increased to 77.20 percent over a span of six months, even after the treatment was stopped at three months. These represent some of the best outcomes reported for treatments of DFUs.

The launch event also saw the presence of many renowned individuals like Premchand Godha, AK Jain, Dr. Anil Pareek, Sunil Ghai, and Supreet Deshpande. This new product is a quantum step forward in the ability to deal with the complications of DFU and improve patient outcomes.